Table 8.
Analysis of pro- and anti-inflammatory markers (PRD; defined as 25% decline in eGFR)
| Pro- and Anti-Inflammatory Markers | Patients without PRD, d0 | Patients with PRD, d0 | P Value | Patients without PRD, d3 | Patients with PRD, d3 | P Value |
|---|---|---|---|---|---|---|
| MIF, median (Q1, Q3), pg/ml | 15,019.2 (10,189.2, 44,648.4) | 16,675.2 (8085.6, 36,628.8) | 0.92 | 11,283.6 (5988.6, 23,681.1) | 6588.0 (3412.8, 12,800.4) | 0.04 |
| IL-6, median (Q1, Q3), pg/ml | 1151.4 (354.1, 1794.9) | 943.9 (210.8, 2175.2) | 0.56 | 282.7 (102.1, 552.1) | 253.6 (100.2, 699.0) | 0.91 |
| IL-8, median (Q1, Q3), pg/ml | 313.6 (123.5, 571.2) | 220.5 (88.6, 443.5) | 0.22 | 73.3 (30.9, 129.2) | 51.4 (16.0, 100.5) | 0.19 |
| IL-10, median (Q1, Q3), pg/ml | 44.6 (20.8, 153.0) | 39.8 (14.9, 101.3) | 0.34 | 22.2 (9.6, 48.6) | 15.3 (9.2, 28.1) | 0.47 |
| IL-18, median (Q1, Q3), pg/ml | 727.0 (343.7, 1153.7) | 565.5 (267.8, 1374.8) | 0.46 | 777.3 (350.9, 1849.6) | 381.2 (241.9, 747.5) | <0.01 |
| TNFR-1, median (Q1, Q3), pg/ml | 1600.3 (1221.1, 2104.9) | 1838.6 (1035.0, 2521.0) | 0.52 | 1447.8 (951.1, 2021.1) | 2058.4 (945.4, 2898.8) | 0.21 |
| TNFR-2, median (Q1, Q3), pg/ml | 22,630.0 (14,873.8, 27,055.0) | 18,577.6 (11,624.6, 27,280.0) | 0.18 | 20,880.0 (11,916.3, 29,420.0) | 20,200.0 (13,090.0, 39,715.0) | 0.48 |
Patients who died within 1 year are excluded; n=39 patients with PRD at 1 year. d0, Blood samples were drawn at the time of randomization; d3, blood samples were drawn 72 h after randomization.